Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-28 04:03:34 - browse：995

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

knowledge

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Woman returns to dialysis after doctors remove transplanted pig kidney

Ionis drug prevents swelling attacks due to hereditary angioedema

Doctors find melanoma drugs effective against rare brain cancer

The Pandemic Treaty must support building strong health systems

explore

Wikipedia

knowledge

Psychedelics group wrestles with new pharma identity

Biden tests positive for Covid

Tori Bowie and the unacceptable rates of Black maternal death

BMI, flaws aside, is found to be useful estimate of body fat in youth

The high cost of giving birth even with insurance

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Tori Bowie and the unacceptable rates of Black maternal death

Ionis drug prevents swelling attacks due to hereditary angioedema

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At ASCO, AstraZeneca reports strong data for breast cancer drug

entertainment

Innovation in antibiotics is ailing. 'Brain drain' may kill it

AI can’t replace a physician’s gut feeling

Why hospitals are withdrawing from US News rankings

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: Palliative care found as helpful given virtually as in person

Cord blood banking comes at a high cost to babies

focus

leisure time

knowledge

focus